U.S. grants Vidac Pharma patent offering broad protection of mode of action underlying its oncology drug candidates
19 sept. 2024 01h00 HE
|
Vidac Pharma Holding PLC
London (UK), September 19 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class...
Vidac Pharma secures approval for next phase of clinical study of lead asset in Cutaneous T-Cell Lymphoma
12 mars 2024 02h30 HE
|
Vidac Pharma Holding PLC
London (UK), March 12, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a...
Vidac Pharma annonce des données positives de l'analyse intermédiaire de phase 2a pour son produit phare VDA-1102 dans le traitement des Lymphomes T cutanés (LCT), une maladie rare.
29 janv. 2024 02h00 HE
|
Vidac Pharma Holding PLC
London (UK), January 29, 2024 - Vidac Pharma Holdings Plc. (Hambourg et Stuttgart : T9G ; ISIN:GB00BM9XQ619 ; WKN : A3DTUQ), société biopharmaceutique d'oncologie de stade clinique, pionnière d'une...
Vidac Pharma reports positive interim Phase 2a data in orphan disease cutaneous T-cell lymphoma (CTCL) with lead asset VDA-1102
29 janv. 2024 02h00 HE
|
Vidac Pharma Holding PLC
London (UK), January 29, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a groundbreaking...
Vidac Pharma va mener une étude de phase 2b du VDA-1102, son candidat médicament pour le traitement de la kératose actinique en collaboration avec CentroDerm
19 déc. 2023 01h00 HE
|
Vidac Pharma Holding PLC
Londres (Royaume-Uni), 19 décembre 2023 – Vidac Pharma Holding Plc (Hambourg et Stuttgart : T9G ; ISIN : GB00BM9XQ619 ; WKN : A3DTUQ), société biopharmaceutique d'oncologie de stade clinique, a...
Vidac Pharma to conduct Phase 2b study for actinic keratosis therapeutic candidate VDA-1102 with CentroDerm
19 déc. 2023 01h00 HE
|
Vidac Pharma Holding PLC
London (UK), December 19, 2023 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company, has completed...